VYCO VYCOR MEDICAL INC
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1424768 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-10.2%
TTM net income YoY-289.2%
TTM EPS YoY0.0%
Revenue 3-yr CAGR6.3%
Net income 3-yr CAGR—
Margins
Gross margin82.4%
Operating margin2.5%
Net margin-3.8%
FCF margin—
EBITDA margin6.0%
Returns
ROE—
ROA-6.7%
ROIC (approx.)—
Asset turnover1.79x
Leverage & solvency
Liabilities / assets557.3%
Debt / equity—
Current ratio0.13x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-2.18x
Accruals ratio-21.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $414,895 | $418,264 | $458,540 | $416,877 | $513,792 | $496,353 | $436,378 | $455,226 |
| Cost of revenue | $61,878 | $73,819 | $83,387 | $81,507 | $61,860 | $81,082 | $77,844 | $57,844 |
| Gross profit | $353,017 | $344,445 | $375,153 | $335,370 | $451,932 | $415,271 | $358,534 | $397,382 |
| R&D expense | — | — | — | $0 | $0 | $4,201 | $5,762 | $6,637 |
| SG&A expense | $310,713 | $322,711 | $315,365 | $357,015 | $404,967 | $345,043 | $350,698 | $356,521 |
| Operating income | $27,424 | $6,851 | $45,808 | -$36,525 | $32,085 | $51,146 | -$12,806 | $19,344 |
| Pretax income | $1,521 | -$19,109 | $20,095 | -$62,379 | $4,990 | $25,713 | -$38,514 | -$6,685 |
| Net income | $738 | -$22,288 | $20,108 | -$62,686 | $4,936 | $23,887 | -$38,563 | -$6,737 |
| EBITDA | $42,304 | $21,734 | $59,788 | -$21,645 | $46,965 | $66,027 | $2,074 | $34,224 |
| EPS (basic) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | -0.01 | — |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | -0.01 | — |
| Weighted avg. shares (diluted) | 33.37M | 33.37M | 33.37M | — | 33.37M | 38.67M | 33.37M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $199,409 | $158,907 | $173,634 | $86,982 | $64,230 | $99,700 | $61,049 | $105,648 |
| Receivables | $185,617 | $202,447 | $194,041 | $218,891 | $326,052 | $202,669 | $229,411 | $245,260 |
| Inventory | $165,291 | $190,508 | $181,910 | $159,202 | $167,415 | $156,033 | $176,373 | $146,084 |
| Current assets | $653,489 | $635,877 | $651,047 | $563,422 | $662,596 | $554,355 | $600,695 | $619,614 |
| PP&E, net | $87,326 | $101,373 | $116,128 | $133,936 | $148,474 | $164,338 | $176,585 | $192,693 |
| Total assets | $964,879 | $813,174 | $854,071 | $830,420 | $941,195 | $878,946 | $940,831 | $998,117 |
| Current liabilities | $5.11M | $4.93M | $4.95M | $4.78M | $4.82M | $4.58M | $4.65M | $4.50M |
| Total liabilities | $5.38M | $5.06M | $5.08M | $4.92M | $4.97M | $4.75M | $4.83M | $4.69M |
| Shareholders' equity | -$4.41M | -$4.25M | -$4.23M | -$4.09M | -$4.02M | -$3.87M | -$3.89M | -$3.69M |
| Shares outstanding | 33.37M | 33.37M | 33.37M | 33.37M | 33.37M | 33.37M | 33.37M | 33.37M |
| Cash flow statement | ||||||||
| Operating cash flow | $5,886 | -$4,843 | $99,422 | $39,232 | -$72,427 | $46,633 | -$26,909 | -$38,281 |
| Capital expenditure | — | — | — | $1,605 | $1 | — | — | -$2 |
| Free cash flow | — | — | — | $37,627 | -$72,428 | — | — | -$38,279 |
| Investing cash flow | -$1,540 | $342 | $2,140 | -$1,606 | $0 | — | — | $170 |
| Financing cash flow | $36,156 | -$10,246 | -$14,910 | -$14,874 | $36,957 | -$5,205 | -$17,690 | -$13,874 |
| Depreciation & amortization | $14,880 | $14,883 | $13,980 | $14,880 | $14,880 | $14,881 | $14,880 | $14,880 |
| Stock-based compensation | — | — | — | $0 | $12,209 | $0 | $18,315 | $18,314 |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.